Molnupiravir was given to people twice a day, for five days at home, while they had the Omicron variant of Covid. Those chosen were at a higher risk of death or hospitalisation from Covid due to ...

Molnupiravir is the first oral antiviral treatment for Covid to report clinical trial results. The first pill designed to treat symptomatic Covid has been approved by the UK medicines regulator ...

The primary efficacy and safety endpoints of the trial ... Authorized Use of LAGEVRIO TM (molnupiravir) in the U.S. LAGEVRIO (molnupiravir) is authorized for use under an Emergency Use ...